查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586050

癌症診斷藥物市場：按診斷類型、適應症、成分和最終用途 - 2025-2030 年全球預測

Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症診斷市值為299.5億美元，預計到2024年將達到333.1億美元，複合年成長率為11.71%，預計到2030年將達到650.6億美元。

癌症診斷市場包括一系列旨在識別癌細胞、癌前病變和患者整體腫瘤負擔的測試和程序。這包括診斷影像，如 MRI 和電腦斷層掃描、血液檢查、切片檢查以及新的遺傳和分子診斷技術。全球範圍內癌症患病率的不斷上升以及對早期檢測和有針對性的治療計劃的需求推動了對癌症診斷的需求，這些計劃可以顯著改善患者的治療結果和生存率。市場的應用涵蓋多種癌症類型，最終用戶包括醫院、診斷實驗室和研究機構。主要成長動力包括技術進步帶來更精確的診斷方法、透過資金和政策舉措增加政府支持以及提高對常規癌症篩檢的認知和採用。最近的商機在於人工智慧整合診斷和液態切片技術的出現，這些技術提供微創、快速和高度準確的診斷選擇。基因組學和個人化醫療的日益融合正在釋放新的市場潛力，並為公司在設計針對特定癌症的診斷方法方面進行創新創造空間。然而，挑戰仍然存在，例如先進診斷工具的成本高昂、監管核准困難以及發展中地區獲得醫療基礎設施的機會有限。此外，癌症類型的多樣性和疾病的複雜性為標準化診斷方案帶來了障礙。投資於非侵入性診斷技術和人工智慧能力的研究對於促進創新至關重要。此外，科技公司和醫療保健提供者之間的夥伴關係可以在早期檢測和治療效果方面帶來突破。了解持有強大研發能力的關鍵參與者主導的競爭格局對於希望在這個充滿活力的市場中導航和擴張的公司至關重要，並且為相關人員提供對新技術和政策變化的洞察力變得至關重要。

主要市場統計
基準年[2023] 299.5億美元
預測年份 [2024] 333.1億美元
預測年份 [2030] 650.6億美元
複合年成長率（%） 11.71%

市場動態：揭示快速發展的癌症診斷市場的關鍵市場洞察

供需的動態交互作用正在改變癌症診斷藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 年輕人和老年人的癌症負擔增加
    • 政府加強癌症意識計劃和宣傳活動
    • 癌症診斷的有利報銷框架
  • 市場限制因素
    • 癌症診斷設備高成本，癌症專家短缺
  • 市場機會
    • 部署癌症篩檢、檢測和診斷的創新工具
    • 奈米技術和奈米材料在癌症診斷中的整合
  • 市場挑戰
    • 癌症診斷藥物的不充分和錯誤結果

波特五力：駕馭癌症診斷市場的策略工具

波特的五力框架是了解癌症診斷市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症診斷藥物市場的影響

外部宏觀環境因素在塑造癌症診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症診斷藥物市場的競爭狀況

對癌症診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣癌症診斷市場供應商績效評估

FPNV定位矩陣是評估癌症診斷​​市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪癌症診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，癌症診斷市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 年輕人和老年人的癌症負擔增加
      • 政府加強癌症意識的努力和宣傳活動
      • 癌症診斷的有利報銷框架
    • 抑制因素
      • 癌症診斷設備高成本，腫瘤科醫師短缺
    • 機會
      • 推出癌症篩檢、檢測和診斷的創新工具
      • 奈米技術和奈米材料在癌症診斷中的整合
    • 任務
      • 癌症診斷藥物的結果不充分且不正確
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按診斷類型分類的癌症診斷藥物市場

  • 切片檢查
  • 血液化學測試
    • 全血球計數 (CBC)
    • 細胞遺傳學分析
    • 免疫表現型分析
    • 液態生物檢體
    • 痰液細胞學檢查
    • 腫瘤標記檢測
    • 尿細胞學檢查
  • 影像檢查
    • 骨骼掃描
    • 電腦斷層掃描
    • 磁振造影(MRI)
    • 核子掃描
    • 正子子斷層掃描 (PET) 掃描
    • 超音波
    • X光

第7章 癌症診斷藥物適應症市場

  • 膀胱癌
  • 血癌
  • 乳癌
  • 大腸直腸癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 胰臟癌
  • 攝護腺癌
  • 皮膚癌

第8章癌症診斷市場：按組成部分

  • 消耗品
  • 裝置
  • 軟體

第9章癌症診斷市場：依最終用途分類

  • 診斷實驗室
  • 醫院
  • 研究中心

第10章北美和南美癌症診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區癌症診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲癌症診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 新資金支持早期癌症平台 Labmate Online 的開發
    • Owlstone Medical 與 Bicycle Therapeutics 合作開發用於早期癌症檢測的抗原標靶 EVOC 探針
    • 癌症診斷公司 GenoME Diagnostics 籌集 140 萬英鎊資金籌措
    • Ibex 的 Galen Prostate 成為第一個獨立的人工智慧癌症診斷解決方案，根據 IVDR 獲得 CE 標誌
    • Dxcover 融資 1000 萬英鎊，用於開發針對早期癌症的突破性液態生物檢體平台
    • 微軟與 Page 合作推廣癌症診斷和治療
    • FUJIFILM India 與 Surya Diagnostics LLP 合作在蒂魯爾啟動電腦斷層掃描
    • Biocare Medical 收購 Empire Genomics
    • Thermo Fisher 與 The Binding Site 簽署價值 26 億美元的協議
    • Ibex Medical 推出 Galen 3.0 癌症診斷平台
    • 羅氏推出用於癌症診斷的新 BenchMark ULTRA PLUS 系統，以實現及時、有針對性的患者照護。
    • Karkinos Healthcare 成立“先進癌症診斷和研究中心”
    • BD 從 Vitro SA 收購了 Cytognos，將其業務從癌症檢測和診斷擴展到治療後監測。
    • Becton Dickinson 收購西班牙臨床流式細胞技術公司 Cytognos
    • EarlySign 宣布策略協議，將用於早期癌症檢測的人工智慧解決方案商業化
    • Cancer Diagnostics, Inc. 收購 Anatech, Ltd.
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • bioMerieux SA
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • Myriad Genetics
  • Natera, Inc.
  • Perkin Elmer, Inc.
  • Personal Genome Diagnostics Inc.
  • Qiagen NV
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-436145BF8B0C

The Cancer Diagnostics Market was valued at USD 29.95 billion in 2023, expected to reach USD 33.31 billion in 2024, and is projected to grow at a CAGR of 11.71%, to USD 65.06 billion by 2030.

The Cancer Diagnostics market encompasses a wide array of tests and procedures aimed at identifying cancerous cells, precancerous conditions, and overall tumor burden in patients. It includes imaging modalities like MRI and CT scans, blood tests, biopsies, and novel genetic and molecular diagnostic techniques. The necessity of cancer diagnostics stems from the growing prevalence of cancer globally, prompting the need for early detection and targeted treatment plans which can significantly improve patient outcomes and survival rates. This market's applications range across various cancer types, with end-users including hospitals, diagnostic laboratories, and research institutions. Key growth drivers include advancements in technology leading to more precise diagnostic methods, increased governmental support through funding and policy initiatives, and growing awareness and adoption of routine cancer screenings. Recent opportunities lie in the advent of AI-integrated diagnostics and liquid biopsy technologies, which offer minimally invasive, rapid, and highly accurate diagnostic options. The ongoing integration of genomics and personal medicine is also set to unlock new market potentials, giving businesses room to innovate in designing specific cancer-targeting diagnostics. However, challenges exist in the form of high costs of advanced diagnostic tools, stringent regulatory approvals, and limited access to healthcare infrastructure in developing regions. Additionally, the variability in cancer types and the complex nature of the disease create barriers to standardized diagnostic protocols. To foster innovation, investment in research focused on non-invasive diagnostic techniques and AI capabilities would be essential. Furthermore, partnerships between technology companies and healthcare providers can lead to breakthroughs in early detection and treatment effectiveness. Understanding the competitive landscape, dominated by key players who hold vast R&D capabilities, is crucial for businesses aiming to navigate and expand in this dynamic market, making continuous monitoring of emerging technologies and policy changes imperative for stakeholders.

KEY MARKET STATISTICS
Base Year [2023] USD 29.95 billion
Estimated Year [2024] USD 33.31 billion
Forecast Year [2030] USD 65.06 billion
CAGR (%) 11.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Diagnostics Market

The Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing burden of cancer among younger and geriatric population
    • Rising government initiatives and campaigns for cancer awareness
    • Favorable reimbursement framework for cancer diagnosis
  • Market Restraints
    • Associated high cost of cancer diagnostic equipment and lack of oncologists
  • Market Opportunities
    • Deployement of innovative tools for cancer screening, detection, and diagnostics
    • Integration of nanotechnology and nanomaterials in cancer diagnosis
  • Market Challenges
    • Inadequate and false results of cancer diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Diagnostics Market

A detailed market share analysis in the Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Diagnostics Market

A strategic analysis of the Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMerieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Type, market is studied across Biopsy, Blood Chemistry Tests, and Imaging Tests. The Blood Chemistry Tests is further studied across Complete Blood Count (CBC), Cytogenetic Analysis, Immunophenotyping, Liquid Biopsy, Sputum Cytology, Tumor Marker Tests, and Urine Cytology. The Imaging Tests is further studied across Bone Scan, CT-Scan, Magnetic Resonance Imaging (MRI), Nuclear Scan, Positron Emission Tomography (PET) Scan, Ultrasound, and X-Rays.
  • Based on Indication, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
  • Based on Components, market is studied across Consumables, Instruments, and Software.
  • Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, and Research Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing burden of cancer among younger and geriatric population
      • 5.1.1.2. Rising government initiatives and campaigns for cancer awareness
      • 5.1.1.3. Favorable reimbursement framework for cancer diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
      • 5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Inadequate and false results of cancer diagnostics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Diagnostics Market, by Diagnostic Type

  • 6.1. Introduction
  • 6.2. Biopsy
  • 6.3. Blood Chemistry Tests
    • 6.3.1. Complete Blood Count (CBC)
    • 6.3.2. Cytogenetic Analysis
    • 6.3.3. Immunophenotyping
    • 6.3.4. Liquid Biopsy
    • 6.3.5. Sputum Cytology
    • 6.3.6. Tumor Marker Tests
    • 6.3.7. Urine Cytology
  • 6.4. Imaging Tests
    • 6.4.1. Bone Scan
    • 6.4.2. CT-Scan
    • 6.4.3. Magnetic Resonance Imaging (MRI)
    • 6.4.4. Nuclear Scan
    • 6.4.5. Positron Emission Tomography (PET) Scan
    • 6.4.6. Ultrasound
    • 6.4.7. X-Rays

7. Cancer Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Bladder Cancer
  • 7.3. Blood Cancer
  • 7.4. Breast Cancer
  • 7.5. Colorectal Cancer
  • 7.6. Kidney Cancer
  • 7.7. Liver Cancer
  • 7.8. Lung Cancer
  • 7.9. Pancreatic Cancer
  • 7.10. Prostate Cancer
  • 7.11. Skin Cancer

8. Cancer Diagnostics Market, by Components

  • 8.1. Introduction
  • 8.2. Consumables
  • 8.3. Instruments
  • 8.4. Software

9. Cancer Diagnostics Market, by End-Use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Research Centers

10. Americas Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
    • 13.3.2. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
    • 13.3.3. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
    • 13.3.4. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
    • 13.3.5. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
    • 13.3.6. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
    • 13.3.7. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
    • 13.3.8. Biocare Medical Acquires Empire Genomics
    • 13.3.9. Thermo Fisher ties up $2.6B deal for The Binding Site
    • 13.3.10. Ibex Medical launches Galen 3.0 cancer diagnostics platform
    • 13.3.11. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
    • 13.3.12. Karkinos Healthcare launches 'Advanced Centre For Cancer Diagnostics and Research'
    • 13.3.13. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
    • 13.3.14. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
    • 13.3.15. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
    • 13.3.16. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies Corporation
  • 3. Agilent Technologies, Inc.
  • 4. Becton, Dickinson & Company
  • 5. Bio-Techne Corporation
  • 6. bioMerieux SA
  • 7. Castle Biosciences Inc.
  • 8. Danaher Corporation
  • 9. Exact Sciences Corporation
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GE Healthcare
  • 12. Hologic Inc.
  • 13. Illumina, Inc.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Konica Minolta, Inc.
  • 16. Koninklijke Philips N.V.
  • 17. Myriad Genetics
  • 18. Natera, Inc.
  • 19. Perkin Elmer, Inc.
  • 20. Personal Genome Diagnostics Inc.
  • 21. Qiagen N.V.
  • 22. Quest Diagnostics
  • 23. Siemens Healthineers AG
  • 24. Sysmex Corporation
  • 25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPLETE BLOOD COUNT (CBC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CYTOGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPUTUM CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY URINE CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BONE SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CT-SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY NUCLEAR SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 154. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 159. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 160. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 175. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 178. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 181. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 185. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 187. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 190. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 193. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 196. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 197. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 199. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 203. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 205. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 208. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 209. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 211. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 214. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 215. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 217. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 220. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 221. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 223. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 226. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 227. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 229. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 232. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 233. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 235. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 238. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 239. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 241. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 244. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 247. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 250. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 251. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 253. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 262. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 263. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 265. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 268. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 269. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 271. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 274. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 275. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 277. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 280. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 281. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 283. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 296. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 297. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023